{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:12:21Z","timestamp":1770966741684,"version":"3.50.1"},"reference-count":125,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The \u201csevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u201d is the third member of human coronavirus (CoV) that is held accountable for the current \u201ccoronavirus disease 2019 (COVID-19)\u201d pandemic. In the past two decades, the world has witnessed the emergence of two other similar CoVs, namely SARS-CoV in 2002 and MERS-CoV in 2013. The extent of spread of these earlier versions was relatively low in comparison to SARS-CoV-2. Despite having numerous reports inclined towards the zoonotic origin of the virus, one cannot simply sideline the fact that no animal originated CoV is thus far identified that is considered similar to the initial edition of SARS-CoV-2; however, under-sampling of the diverse variety of coronaviruses remains a concern. Vaccines are proved to be an effective tool for bringing the end to such a devastating pandemic. Many vaccine platforms are explored for the same but in this review paper, we will discuss the potential of replicating viral vectors as vaccine carriers for SARS-CoV-2.<\/jats:p>","DOI":"10.3390\/v14040759","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T22:23:23Z","timestamp":1649370203000},"page":"759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena"],"prefix":"10.3390","volume":"14","author":[{"given":"Vivek P.","family":"Chavda","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"},{"name":"Department of Pharmaceutics, K B Institute of Pharmaceutical Education and Research, Kadi Sarva Vishwavidhyalaya, Gandhinagar 382023, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajashri","family":"Bezbaruah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansi","family":"Athalye","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palak K.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry and Quality Assurance, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-1162","authenticated-orcid":false,"given":"Abu Sufiyan","family":"Chhipa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-2771","authenticated-orcid":false,"given":"Vasso","family":"Apostolopoulos","sequence":"additional","affiliation":[{"name":"Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jiph.2021.11.009","article-title":"Childhood Vaccination Hesitancy in Saudi Arabia: A Time for Action","volume":"15","author":"Alamer","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A Guide to Vaccinology: From Basic Principles to New Developments","volume":"21","author":"Pollard","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.36953\/ECJ.2021.SE.2207","article-title":"Biotherapeutics and Its Applications in Microbiology","volume":"22","author":"Kaur","year":"2021","journal-title":"Environ. Conserv. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14760584.2021.1987223","article-title":"DNA Vaccines for SARS-CoV-2: Towards Third Generation Vaccination Era","volume":"20","author":"Chavda","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","first-page":"63","article-title":"Vaccines in Historic Evolution and Perspective: A Narrative of Vaccine Discoveries","volume":"3","author":"Hilleman","year":"2000","journal-title":"J. Hum. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1086\/374419","article-title":"Vaccines, Vaccination, and Vaccinology","volume":"187","author":"Plotkin","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kallerup, R.S., and Foged, C. (2015). Classification of Vaccines. Subunit Vaccine Delivery, Springer.","DOI":"10.1007\/978-1-4939-1417-3_2"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yadav, D.K., Yadav, N., and Khurana, S.M.P. (2020). Vaccines: Present Status and Applications. Animal Biotechnology, Academic Press.","DOI":"10.1016\/B978-0-12-811710-1.00024-0"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal Vaccines for SARS-CoV-2: From Challenges to Potential in COVID-19 Management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.ccmp.2021.100004","article-title":"COVAX-19 Vaccine: Completely Blocks Virus Transmission to Non-Immune Individuals","volume":"1","author":"Chavda","year":"2021","journal-title":"Clin. Complement. Med. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Uddin, M., Mustafa, F., Rizvi, T.A., Loney, T., Al Suwaidi, H., Al-Marzouqi, A.H.H., Eldin, A.K., Alsabeeha, N., Adrian, T.E., and Stefanini, C. (2020). SARS-CoV-2\/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses, 12.","DOI":"10.20944\/preprints202004.0005.v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3389\/fimmu.2020.585354","article-title":"A Review of the Progress and Challenges of Developing a Vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.ijbiomac.2021.10.172","article-title":"SARS-COV-2, Infection, Transmission, Transcription, Translation, Proteins, and Treatment: A Review","volume":"193","author":"Emrani","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/biologics1030020","article-title":"Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena","volume":"1","author":"Chavda","year":"2021","journal-title":"Biologics"},{"key":"ref_15","unstructured":"(2021, December 09). WHO COVID-19 Vaccine Tracker and Landscape. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_16","unstructured":"WHO (2021). COVID19 Vaccine Tracker, WHO."},{"key":"ref_17","first-page":"e934625","article-title":"V Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy","volume":"27","author":"Parums","year":"2021","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants versus Efficacy, Effectiveness and Escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112550","DOI":"10.1016\/j.biopha.2021.112550","article-title":"A Critical Analysis of SARS-CoV-2 (COVID-19) Complexities, Emerging Variants, and Therapeutic Interventions and Vaccination Strategies","volume":"146","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(21)02841-5","article-title":"Managing Waning Vaccine Protection against SARS-CoV-2 Variants","volume":"399","author":"Leung","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"690621","DOI":"10.3389\/fcimb.2021.690621","article-title":"COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions","volume":"11","author":"Khan","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_22","first-page":"4","article-title":"What Is the Vaccine Effect on Reducing Transmission in the Context of the SARS-CoV-2 Delta Variant?","volume":"380","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11673-020-10025-8","article-title":"In the Shadow of Biological Warfare: Conspiracy Theories on the Origins of COVID-19 and Enhancing Global Governance of Biosafety as a Matter of Urgency","volume":"17","author":"Nie","year":"2020","journal-title":"J. Bioeth. Inq."},{"key":"ref_25","first-page":"2928","article-title":"Inoculating Against Fake News About COVID-19","volume":"11","author":"Roozenbeek","year":"2020","journal-title":"Front. Psychol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1473-3099(20)30641-1","article-title":"The Origin of SARS-CoV-2","volume":"20","author":"Burki","year":"2020","journal-title":"Lancet. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41591-020-01205-5","article-title":"On the Origins of SARS-CoV-2","volume":"27","author":"Rasmussen","year":"2021","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Feehan, J., and Apostolopoulos, V. (2021). A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals. Vaccines, 9.","DOI":"10.3390\/vaccines9060631"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.virusres.2014.05.026","article-title":"Coronavirus Reverse Genetic Systems: Infectious Clones and Replicons","volume":"189","author":"Sola","year":"2014","journal-title":"Virus Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/JVI.02041-07","article-title":"Mechanisms of Zoonotic Severe Acute Respiratory Syndrome Coronavirus Host Range Expansion in Human Airway Epithelium","volume":"82","author":"Sheahan","year":"2008","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fpubh.2020.596944","article-title":"COVID-19\u2014Zoonosis or Emerging Infectious Disease?","volume":"8","author":"Haider","year":"2020","journal-title":"Front. Public Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-2019 (COVID-19): The Epidemic and the Challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_35","first-page":"100013","article-title":"Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment","volume":"3","author":"Chavda","year":"2021","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3389\/fimmu.2020.552909","article-title":"Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses","volume":"11","author":"Abdelrahman","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and Evolution of Pathogenic Coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10311-020-01151-1","article-title":"Tracing the Origins of SARS-COV-2 in Coronavirus Phylogenies: A Review","volume":"19","author":"Sallard","year":"2021","journal-title":"Environ. Chem. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.meegid.2019.03.001","article-title":"Molecular Epidemiology, Evolution and Phylogeny of SARS Coronavirus","volume":"71","author":"Luk","year":"2019","journal-title":"Infect. Genet. Evol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jiph.2020.06.017","article-title":"Co-Infection of MERS-CoV and SARS-CoV-2 in the Same Host: A Silent Threat","volume":"13","author":"Baddal","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/nm.3985","article-title":"A SARS-like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3201\/eid2607.200092","article-title":"Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2","volume":"26","author":"Lau","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104212","DOI":"10.1016\/j.meegid.2020.104212","article-title":"Full-Genome Evolutionary Analysis of the Novel Corona Virus (2019-NCoV) Rejects the Hypothesis of Emergence as a Result of a Recent Recombination Event","volume":"79","author":"Paraskevis","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hu, B., Zeng, L.P., Yang, X.L., Ge, X.Y., Zhang, W., Li, B., Xie, J.Z., Shen, X.R., Zhang, Y.Z., and Wang, N. (2017). Discovery of a Rich Gene Pool of Bat SARS-Related Coronaviruses Provides New Insights into the Origin of SARS Coronavirus. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006698"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104493","DOI":"10.1016\/j.meegid.2020.104493","article-title":"COVID-19: Time to Exonerate the Pangolin from the Transmission of SARS-CoV-2 to Humans","volume":"84","author":"Frutos","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.cub.2020.03.022","article-title":"Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak","volume":"30","author":"Zhang","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The Proximal Origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhang, T., Wu, Q., and Zhang, Z. (Curr. Biol., 2020). Pangolin Homology Associated with 2019-NCoV, Curr. Biol., Preprint.","DOI":"10.1101\/2020.02.19.950253"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wei, C., Shan, K.-J., Wang, W., Zhang, S., Huan, Q., and Qian, W. (2021). Evidence for a Mouse Origin of the SARS-CoV-2 Omicron Variant. J. Genet. Genomics.","DOI":"10.1101\/2021.12.14.472632"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.7150\/ijbs.45472","article-title":"Zoonotic Origins of Human Coronaviruses","volume":"16","author":"Ye","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Seidah, N.G., Pasquato, A., and Andr\u00e9o, U. (2021). How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?. Viruses, 13.","DOI":"10.20944\/preprints202104.0469.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.crphar.2022.100086","article-title":"Therapeutics for COVID-19 and Post COVID-19 Complications: An Update","volume":"3","author":"Basu","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.maturitas.2022.01.011","article-title":"Omicron Variant (B.1.1.529) of SARS-CoV-2: Threat for the Elderly?","volume":"158","author":"Chavda","year":"2022","journal-title":"Maturitas"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/imt-2021-0168","article-title":"A Global Picture: Therapeutic Perspectives for COVID-19","volume":"14","author":"Chavda","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., and Apostolopoulos, V. (Expert Rev. Vaccines, 2022). Global Impact of Delta plus Variant and Vaccination, Expert Rev. Vaccines, Preprint.","DOI":"10.1080\/14760584.2022.2044800"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Patel, A.B., Vihol, D., Vaghasiya, D.D., Ahmed, K.M.S.B., Trivedi, K.U., and Dave, D.J. (Clin. Complement. Med. Pharmacol., 2022). Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update, Clin. Complement. Med. Pharmacol., in press.","DOI":"10.1016\/j.ccmp.2022.100021"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., and Apostolopoulos, V. (2022). Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?. Vaccines, 10.","DOI":"10.3390\/vaccines10030367"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100124","DOI":"10.1016\/j.onehlt.2020.100124","article-title":"From SARS to COVID-19: A Previously Unknown SARS- Related Coronavirus (SARS-CoV-2) of Pandemic Potential Infecting Humans\u2014Call for a One Health Approach","volume":"9","year":"2020","journal-title":"One Heal."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMp2029466","article-title":"Vaccine Innovations\u2014Past and Future","volume":"384","author":"Gerberding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1073\/pnas.69.10.2904","article-title":"Biochemical Method for Inserting New Genetic Information into DNA of Simian Virus 40: Circular SV40 DNA Molecules Containing Lambda Phage Genes and the Galactose Operon of Escherichia Coli","volume":"69","author":"Jackson","year":"1972","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-Associated Virus Vector as a Platform for Gene Therapy Delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kandimalla, R., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P.H., De Feo, V., and Dewanjee, S. (2021). Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomed., 9.","DOI":"10.31219\/osf.io\/uy7mp"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Chanukya, G.V., and Srikantam, A. (medRxiv, 2021). Comparative Quantitative Analysis of SARS-CoV-2 Spike Neutralizing Antibody Titers Following Two Anti COVID-19 Vaccines in India, medRxiv, in press.","DOI":"10.1101\/2021.08.28.21262753"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and Safety of SARS-CoV-2 Vaccine in Real-World Studies: A Systematic Review and Meta-Analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"106569","DOI":"10.1016\/j.rmed.2021.106569","article-title":"Controversy Surrounding the Sputnik V Vaccine","volume":"187","author":"Cazzola","year":"2021","journal-title":"Respir. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"112353","DOI":"10.1016\/j.biopha.2021.112353","article-title":"A Comprehensive Review on Efficient Approaches for Combating Coronaviruses","volume":"144","author":"Pouresmaieli","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jiph.2021.12.014","article-title":"The SARS-CoV-2 Mutations versus Vaccine Effectiveness: New Opportunities to New Challenges","volume":"15","author":"Malik","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 Vaccines for Their Characteristics, Efficacy and Effectiveness against SARS-CoV-2 and Variants of Concern: A Narrative Review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., and Dabrera, G. (2022). Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2115481"},{"key":"ref_72","unstructured":"Cascella, M., Rajnik, M., and Aleem, A. (2022, January 24). Features, Evaluation, and Treatment of Coronavirus (COVID-19), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 Vaccines: Where We Stand and Challenges Ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"635337","DOI":"10.3389\/fmolb.2021.635337","article-title":"Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19","volume":"8","author":"Bezbaruah","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and Non-Replicating Viral Vectors for Vaccine Development","volume":"18","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/d41586-020-01221-y","article-title":"The Race for Coronavirus Vaccines: A Graphical Guide","volume":"580","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S Vaccine against SARS-CoV-2 Variants in Humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"ref_79","unstructured":"WHO (2021). The Janssen Ad26.COV2.S COVID-19 Vaccine: What You Need to Know, WHO."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","article-title":"Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 NCoV-19\/AZD1222 Vaccine","volume":"7","author":"Watanabe","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Dicks, M.D.J., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., Hill, A.V.S., and Cottingham, M.G. (2012). A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040385"},{"key":"ref_82","unstructured":"World Health Organization (WHO) (2022). The Oxford\/AstraZeneca (ChAdOx1-S [Recombinant] Vaccine) COVID-19 Vaccine: What You Need to Know, WHO."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"328","DOI":"10.53854\/liim-2903-3","article-title":"Review of COVID-19 Viral Vector-Based Vaccines and COVID-19 Variants","volume":"29","author":"Vanaparthy","year":"2021","journal-title":"Infez. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fmed.2021.684151","article-title":"Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence","volume":"8","author":"Klassen","year":"2021","journal-title":"Front. Med."},{"key":"ref_85","unstructured":"(2022, January 12). Hindustan Times. All You Need to Know about SII Vaccine \u2018Covishield\u2019|10 Points|Latest News India Hindustan Times. Available online: https:\/\/www.hindustantimes.com\/india-news\/ingredients-side-effects-response-time-all-you-need-to-know-about-covishield-101610469717522.html."},{"key":"ref_86","unstructured":"(2022, January 12). Business Standard. Rejection of Sputnik V by US, EU a Mistake: Argentine Epidemiologist. Business Standard News. Available online: https:\/\/www.business-standard.com\/article\/international\/rejection-of-sputnik-v-by-us-eu-a-mistake-argentine-epidemiologist-121122800647_1.html."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Patel, A.B., and Vaghasiya, D.D. (J. Med. Virol., 2022). SARS-CoV-2 variants and vulnerability at the global level, J. Med. Virol., Epub ahead of print.","DOI":"10.1002\/jmv.27717"},{"key":"ref_88","unstructured":"PHO (2021). COVID-19 Vaccines: Viral Vector-Based Vaccines The Basics: Viral Vector-Based Vaccines, Public Health Ontario."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3 Candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of Action of Adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging Concepts in the Science of Vaccine Adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-Generation Vaccine Platforms for COVID-19","volume":"19","year":"2020","journal-title":"Nat. Mater."},{"key":"ref_93","unstructured":"Mayo Clinic (2020). Different Types of COVID-19 Vaccines: How They Work, Mayo Clinic."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors Which Contribute to the Immunogenicity of Non-Replicating Adenoviral Vectored Vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral Vector Vaccine Platforms in the SARS-CoV-2 Pandemic","volume":"6","author":"Lorincz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 NCoV-19) Covid-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis","volume":"114","author":"Zheng","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3389\/fphar.2020.00937","article-title":"A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic","volume":"11","author":"Funk","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_99","unstructured":"World Health Organization (WHO) (2020). List of Candidate Vaccines Developed against SARS-CoV, WHO."},{"key":"ref_100","unstructured":"McGill COVID19 Vaccine Tracker Team (2022, February 11). COVID-19 VACCINE TRACKER. Available online: https:\/\/covid19.trackvaccines.org\/vaccines\/."},{"key":"ref_101","unstructured":"KBR (2021). Cellid\u2019s Covid-19 Vaccine Candidate Shows No Difference between Middle, High Doses, Korea Biomedical Review."},{"key":"ref_102","unstructured":"U.S. National Library of Medicine (2021). Evaluate the Safety, Immunogenicity and Potential Efficacy of an RVSV-SARS-CoV-2-S Vaccine, U.S. National Library of Medicine."},{"key":"ref_103","unstructured":"U.S. National Library of Medicine (2021). Phase 2b\/3 Trial of VSV-\u0394G SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine, U.S. National Library of Medicine. (BRILIFE002)."},{"key":"ref_104","unstructured":"Chinese Clinical Trail Registry (2021). A Phase I Clinical Trial of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-NCoV-RBD-OPT1), U.S. National Library of Medicine."},{"key":"ref_105","unstructured":"U.S. National Library of Medicine (2021). A Phase II Clinical Trial of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-NCoV-RBD-OPT1), U.S. National Library of Medicine."},{"key":"ref_106","unstructured":"U.S. National Library of Medicine (2021). A Phase III Clinical Trial of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-NCoV-RBD-OPT1), U.S. National Library of Medicine."},{"key":"ref_107","unstructured":"U.S. National Library of Medicine (2021). Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers, U.S. National Library of Medicine."},{"key":"ref_108","unstructured":"U.S. National Library of Medicine (2021). Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19, U.S. National Library of Medicine."},{"key":"ref_109","unstructured":"U.S. National Library of Medicine (2021). Phase I\u2013II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults, U.S. National Library of Medicine."},{"key":"ref_110","unstructured":"U.S. National Library of Medicine (2021). Dendritic Cell Vaccine to Prevent COVID-19, U.S. National Library of Medicine."},{"key":"ref_111","unstructured":"U.S. National Library of Medicine (2021). Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection, U.S. National Library of Medicine."},{"key":"ref_112","unstructured":"U.S. National Library of Medicine (2021). Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC), U.S. National Library of Medicine."},{"key":"ref_113","unstructured":"U.S. National Library of Medicine (2021). Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19, U.S. National Library of Medicine."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Pavel, S.T.I., Yetiskin, H., Uygut, M.A., Aslan, A.F., Ayd\u0131n, G., \u0130nan, \u00d6., Kaplan, B., and Ozdarendeli, A. (2021). Development of an Inactivated Vaccine against SARS CoV-2. Vaccines, 9.","DOI":"10.3390\/vaccines9111266"},{"key":"ref_115","unstructured":"U.S. National Library of Medicine (2021). A Synthetic MVA-Based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19 Infection, U.S. National Library of Medicine."},{"key":"ref_116","unstructured":"U.S. National Library of Medicine (2021). SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer, U.S. National Library of Medicine."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Eroglu, B., Nuwarda, R.F., Ramzan, I., and Kayser, V. (2022). A Narrative Review of COVID-19 Vaccines. Vaccines, 10.","DOI":"10.3390\/vaccines10010062"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s13346-021-01001-9","article-title":"Mucosal and Transdermal Vaccine Delivery Strategies against COVID-19","volume":"12","author":"Kumar","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_120","first-page":"14","article-title":"Nasal Medication Conveyance Framework: An Approach for Brain Delivery from Essential to Cutting Edge","volume":"6","author":"Shah","year":"2016","journal-title":"Res. Rev. J. Med."},{"key":"ref_121","unstructured":"U.S. National Library of Medicine (2021). A Phase I Clinical Trial of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-NCoV-RBD-OPT1), U.S. National Library of Medicine."},{"key":"ref_122","unstructured":"U.S. National Library of Medicine (2021). A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine, U.S. National Library of Medicine."},{"key":"ref_123","unstructured":"Health Research Authority (2021). A First in Human Study of OraPro-COVID-19 in Healthy Volunteers, Health Research Authority."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"26463","DOI":"10.1039\/D1RA04835J","article-title":"Nanomaterial-Based Drug Delivery Systems as Promising Carriers for Patients with COVID-19","volume":"11","author":"Olojede","year":"2021","journal-title":"RSC Adv."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.drudis.2020.06.020","article-title":"Emerging Vaccine Delivery Systems for COVID-19 Functionalised Silica Nanoparticles Offer a Potentially Safe and Effective Alternative Delivery System for DNA\/RNA Vaccines","volume":"25","author":"Theobald","year":"2020","journal-title":"Drug Discov. Today"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/759\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:03Z","timestamp":1760136543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":125,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["v14040759"],"URL":"https:\/\/doi.org\/10.3390\/v14040759","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]}}}